News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xcovery Presents Interim Phase 1 Results Of X-396 In ALK Positive NSCLC At The American Society of Clinical Oncology Annual Meeting



6/3/2014 9:59:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Xcovery, a developer of next-generation targeted therapeutics for cancer, today presented preliminary results at the annual meeting of the American Society for Clinical Oncology (ASCO) from a phase 1 study of X-396, a potent small molecule anaplastic lymphoma kinase (ALK) inhibitor, that showed X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES